Interest. No interest shall accrue on the unpaid principal balance of this Note.

Interest. This Note shall be non-interest bearing.

Interest. From the Effective Date until such date as this Loan (together with all interest thereon) is paid in full, the principal balance of this Note outstanding (together with any accrued but unpaid interest thereon) shall bear interest at a per annum interest rate equal to the long term Applicable Federal Rate (as such term is defined in Section 1274(d) of the Internal Revenue Code of 1986, as amended).

Interest. Interest on the Loans shall accrue at the rate of 5.00% per annum from the date of each Loan until the Loans are repaid in full. Interest shall be calculated on the basis of the actual number of days elapsed (including the first day but excluding the last day) but computed as if each calendar year consisted of 360 days. All interest determinations and calculations by Lender are presumptively correct absent manifest error. Accrued interest is due and payable quarterly in arrears on the last day of each quarter, beginning on March 31, 2021.

Interest. The outstanding principal balance of this Note shall bear interest (computed on the basis of a 360-day year, actual days elapsed) either # at a fluctuating rate per annum determined by [[Organization B:Organization]] to be one percent (1.00%) above Daily Simple SOFR in effect from time to time, or # at a fixed rate per annum determined by [[Organization B:Organization]] to be one percent (1.00%) above Term SOFR in effect on the first day of the applicable Interest Period. [[Organization B:Organization]] is hereby authorized to note the date, principal amount and interest rate applicable to this Note and any payments made thereon on [[Organization B:Organization]]’s books and records (either manually or by electronic entry) and/or on any schedule attached to this Note, which notations shall be prima facie evidence of the accuracy of the information noted. [[Organization B:Organization]] shall be permitted to estimate the amount of accrued interest that is payable at any time hereunder on the applicable invoice provided by [[Organization B:Organization]] to [[Organization A:Organization]] in respect thereof, in which case [[Organization A:Organization]] shall pay such estimated amount and [[Organization B:Organization]] shall to the extent necessary, include on the next invoice an adjustment to correct any difference between the amount on the applicable invoice and the amount of interest that actually accrued pursuant to the terms of this Note.

Interest. Subject to the provisions of [Section 2.08(b), (i)])] each Eurodollar RateSOFR Loan shall bear interest on the outstanding principal amount thereof for each Interest Period at a rate per annum equal to the Eurodollar Rate for suchTerm SOFR for the Interest Period in effect for such Loans plus the Applicable Rate; # each Base RateABR Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Alternate Base Rate as in effect from time to time plus the Applicable Rate; and # each Swing Line Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Alternate Base Rate as in effect from time to time plus the Applicable Rate.

Interest. The principal amount of this Note outstanding from time to time shall not bear interest at anytime.

Interest. Interest shall accrue on the principal amount advanced pursuant to this Note at the rate of 4% per annum commencing on the date of this Note.

Interest. Interest is to be accrued on the account balance at a rate of interest that is equal to 120% of the long-term Applicable Federal Rate, adjusted monthly, as published each month by the Internal Revenue Service and available at www.irs.gov. 1

SRSG Common Stock. Prior to the Closing Date, SRSG shall designate an exchange agent acceptable to BioSculpture to act as the agent for the purpose of paying the Merger Consideration in exchange for the BioSculpture Common Stock pursuant to this Agreement, which exchange agent shall be the transfer agent customarily used by SRSG for transfers of SRSG Common Stock or such other competent exchange agent that shall be agreed upon by SRSG and BioSculpture (the “Exchange Agent”). Upon or promptly following the Effective Time, SRSG shall deposit with the Exchange Agent, for exchange in accordance with this Article 2, the aggregate Merger Consideration. The Merger Consideration shall be deposited by delivering to the Exchange Agent certificates representing the shares of SRSG Common Stock or by furnishing to the Exchange Agent shares of SRSG Common Stock allocated for issuance as uncertificated shares or shares represented by book entries.